Cover of Clinical and Economic Review Report: Vedolizumab (ENTYVIO SC)

Clinical and Economic Review Report: Vedolizumab (ENTYVIO SC)

Takeda Canada Inc.

Indication: Crohn disease

CADTH Common Drug Review

Copyright © 2021 Canadian Agency for Drugs and Technologies in Health.
Read

The objective of the current review was to perform a review of the beneficial and harmful effects of vedolizumab subcutaneous in adult patients with moderately to severely active Crohn disease who have had an inadequate response with, lost response to, or were intolerant to immunomodulators or a tumour necrosis factor alpha antagonist; or have had an inadequate response, intolerance, or demonstrated dependence on corticosteroids.